Real-World Clinical Outcomes and Pharmacy-Dispensing Patterns of Ruxolitinib Cream in Non-Segmental Vitiligo: A Retrospective Observational Study

Background/Objectives: Real-world data on the effectiveness, safety, and utilization of topical ruxolitinib in non-segmental vitiligo (NSV) remain limited. The aim of this study was to evaluate the clinical outcomes and safety of ruxolitinib cream in patients with NSV, characterize real-world treatment utilization based on pharmacy dispensing data, and explore its association with disease severity and clinical improvement. Methods: This retrospective observational study included patients with NSV treated with ruxolitinib cream for at least 24 weeks. Disease severity was assessed at baseline and after 12 and 24 weeks using total and facial body surface area (T-BSA and F-BSA) and Vitiligo Area Scoring Index (T-VASI and F-VASI). Treatment utilization was estimated from monthly pharmacy dispensing data. Results: Forty-one patients were included. Mean age was 48.3 years and 65.9% of patients were female. The mean amount of ruxolitinib cream dispensed was 151 ± 134 g/month. Significant reductions were observed in F-BSA and F-VASI (both p < 0.001), T-BSA (p = 0.02), and T-VASI (p < 0.001). No statistically significant association was detected between monthly dispensed quantity and baseline disease severity or clinical improvement at 12 or 24 weeks (all p > 0.50). Adverse events were mild and predominantly local. Conclusions: Ruxolitinib cream was associated with significant clinical improvement in real-world NSV, particularly in facial involvement. No statistically significant association was detected between dispensed quantity and clinical improvement.